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quetiapine extended release effective but that it is also a cost-effective alternative 
compared with paroxetine and lithium in the management of adult patients with acute 
bipolar depression.
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COST-EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE VERSUS 
OTHER ATYPICAL ANTIPSYCHOTICS IN ACUTE BIPOLAR DEPRESSION
Meier G, Edwards SJ, von Maltzahn R
AstraZeneca UK Ltd, Luton, UK
OBJECTIVES: To evaluate the cost-effectiveness of quetiapine extended release 
300 mg once daily (o.d.) in adult patients with acute bipolar depression compared 
with other atypical antipsychotics. METHODS: A systematic literature review was 
conducted to inform a mixed treatment comparison utilising a Markov Chain Monte 
Carlo simulation comprising of a random effects model to estimate the risk of remis-
sion, treatment-emergent mania, discontinuations, signiﬁcant weight-gain (q7%) and 
extrapyramidal adverse event. A weekly cycle 7-state markov model was designed to 
evaluate the cost-effectiveness of quetiapine extended release over a 3-year time 
horizon from the perspective of the UK National Health Service. A systematic litera-
ture review was completed to identify suitable health state utility values. Costs 
included pharmacological therapy and resource use associated with the treatment of 
mood events. Results were reported in cost (2009 values) per quality-adjusted life 
years (QALYs). A probabilistic sensitivity analysis (PSA) was conducted to assess the 
robustness of the results. RESULTS: The literature review only identiﬁed two other 
atypical antipsychotics with a sufﬁcient quality of data to be included in the analysis, 
olanzapine 10 mg and aripiprazole 15 mg (In the aripiprazole trials, aripiprazole did 
not reach signiﬁcance at 8-weeks versus placebo, the data was included for complete-
ness). Quetiapine extended release was a cost-effective (cost: £11,568; QALYs: 2.351) 
treatment option dominating both olanzapine (cost: £11,584; QALYs: 2.347) and 
aripiprazole (cost: £11,773; QALYs: 2.328). These results were supported in the 
probabilistic sensitivity analysis. CONCLUSIONS: The results of this cost-utility 
analysis suggest that not only is quetiapine extended release effective but that it is also 
a cost-effective alternative versus other atypical antipsychotics in the management of 
adult patients with acute bipolar depression.
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OBJECTIVES: To describe the concordance between remission according to clinical 
diagnostic orientation and remission obtained from the computerized databases of 
patients with major depression (MD) in a Spanish population. METHODS: Design: 
multicenter transversal. The assessed population was comprised by people over 17 
from reformed primary care facilities, who had a MD episode between January 2003 
and March 2007. A specialist in psychiatry assessed a random sample of patient his-
tories and determined whether a certain patient was in remission according to clinical 
criteria. Regarding the databases, patients were considered in remission when they did 
not need further prescriptions of AD for at least 6 months after completing treatment 
for a new episode. Validity indicators (sensitivity [S], speciﬁcity [Sp]) and clinical 
utility (positive and negative probability ratio [PPR] and [NPR]) were calculated. The 
concordance index was established using Cohen’s kappa coefﬁcient. Signiﬁcance level 
was p  0.05. RESULTS: 4,572 subjects were analyzed. 54.6% (CI of 95%: 53.2–
56.0%) were considered in remission. Patients in remission showed lower: age (52.6 
vs. 60.7), proportion of women (71.7% vs. 78.2%), general morbidity (6.2 vs. 7.7 
episodes/year), RUB/year (2.7 vs. 3.0), sick leave days (31.0 vs. 38.5) and treatment 
duration (146.6 vs. 307.7 days); p  0.01. 133 patient histories were reviewed. The 
kappa coefﬁcient was 82.8% (conﬁdence intervals [CI] were 95%: 73.1—92.6), PPR 
9.8% and NPR 0.1%. Allocation discrepancies between both criteria were found in 
11 patients. S was 92.5% (CI was 95%: 88.0–96.9%) and Sp was 90.6% (CI was 
95%: 85.6–95.6%), p  0.001. Reliability analysis: Cronbach’s alpha: 90.6% (CI was 
95%: 85.6–95.6%). CONCLUSIONS: Results show an acceptable level of concor-
dance between remission obtained from the computerized databases and clinical 
 criteria. The major discrepancies were found in diagnostic accuracy.
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OBJECTIVES: Bipolar disorder is a serious mental illness characterized by cyclical 
periods of depression and euphoria. Few studies have evaluated the inpatient burden 
of bipolar disorder among pediatrics. This study explored rates of hospitalization, 
length of stay (LOS), and total charges (TC) associated with bipolar disorder in a 
pediatric population over a six-year period. METHODS: Data were taken from the 
2000–2005 Healthcare Cost and Utilization Project Nationwide Inpatient Samples, 
nationally representative databases of United States (US) hospital stays. Pediatric (a19 
years) patients with a primary diagnosis of bipolar disorder (ICD-9-CM codes 296.0 
and 296.5–296.9) were analyzed. Weighted, age-standardized hospitalization rates, 
patient demographics, and estimates of TC and LOS were assessed. RESULTS: 
Over the 6-year study period, 212,964 pediatric visits with a primary diagnosis of 
bipolar disorder were identiﬁed. Mean (oSD) age was 14.7 (o3.4) years and 48.7% 
were female. Most (47.8%) were routine admissions, and the majority was covered 
by private insurance (51.2%). The age-standardized rate of bipolar disorder-related 
hospitalizations (per 10,000 2008 US pediatric population) rose slightly from 2000 to 
2005, from 3.4/10,000 to 3.8/10,000, with a low of 2.8/10,000 in 2002 and a high 
of 4.2/10,000 in 2003. Early in the decade, the mean LOS rose (8.2 days in 2000 to 
9.6 in 2002), but then declined, to 7.8 days in 2005. Similarly, mean TC (2008 US$) 
for a bipolar disorder-related stay increased between 2000 and 2002 ($12,744 to 
$16,567, respectively), and then declined over the next 3 years, to $13,736 in 2005. 
CONCLUSIONS: We examined trends in rates of bipolar disorder-related hospitaliza-
tions and associated outcomes among pediatric patients. We observed fairly stable rates 
of hospitalizations over the 6-year study period. However, LOS and TC exhibited an 
initial rise and subsequent decline. Health care stakeholders should be cognizant of the 
effect that bipolar disorder may have on hospitalizations and related resource use.
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OBJECTIVES: Previous studies have demonstrated the ability to collect patient-
reported outcomes from members of an on-line patient community with chronic condi-
tions. In this pilot study, we explore the feasibility of capturing health resource 
utilization data from a vulnerable population, schizophrenics. METHODS: To iden-
tify 50 subjects, we screened 369 iGuard.org members taking at least one anti- 
psychotic: aripiprazole, clozapine, haloperidol, olanzapine, paliperidone, quetiapine, 
risperdone, or ziprasidone. iGuard.org is a medication monitoring service that pro-
vides drug safety information to over 1.4 million US members. Subjects completed an 
on-line survey regarding health resource use in the past 6 months and 2 years, among 
other questions. RESULTS: A total of 45 of 50 respondents (90%) identiﬁed them-
selves as a patient; 10% were caregivers. Most respondents (80%) are managed by 
a psychiatrist and have experienced metabolic symptoms: 68% gained 11 pounds, 
14% gained 10 pounds or less, 38% were diagnosed with high cholesterol, and 10% 
developed diabetes. Only 16% have not experienced metabolic symptoms. With 
respect to resource utilization, 44% visited the ER, 24% were hospitalized, and 12% 
were arrested, jailed, or imprisoned in the past 6 months. Utilization within the last 
2 years was as follows: 68% visited the ER, 40% were hospitalized, and 12% were 
arrested. Responses were inconsistent for a total of 5 of 50 patients who indicated use 
within the past 6 months, but not within 2 years in at least one of the three resource 
categories. CONCLUSIONS: The results of this study suggest that although research-
ers should continue to examine patient reported data for inconsistencies, patient 
communities can be a time and cost-efﬁcient source of patient-reported outcomes data 
such as health resource utilization even for vulnerable populations.
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OBJECTIVES: To identify utilization patterns of health care resources for psychoso-
cial supports in Japanese psychiatric outpatients. METHODS: A one-day survey was 
conducted at 109 outpatient mental clinics from members of the Japanese Association 
of Neuro-Psychiatric Clinics during the period from December 10 to 16, 2008. All 
patients who visited the clinics on the day of survey were subjected to the study and 
medical staffs ﬁlled out questionnaires on patients’ socio-demographic and clinical 
status including information about resource utilization for psychosocial supports. 
RESULTS: Among total 4689 patients, 42.2% were male. The mean / SD age was 
47.1 o 17.2 years. More than two thirds of patients (37.9%) were diagnosed as mood 
disorders (ICD-10 F3), followed by neurotic disorders (F4: 27.7%), psychotic disor-
ders (F2: 20.0%), organic mental disorders (F0: 2.7%) and other diagnosis (8.8%). 
18.9% patients had been hospitalized at psychiatric institutions at least once. 9.8% 
consulted medical staffs such as psychologists and social workers, in addition to psy-
chiatrists. 4.2% of patients utilized day/nightcare programs covered by health insur-
ance. Utilization rate of community services including community workshops, support 
service for employment, local activity support center, rehabilitation service and other 
psychosocial resources were 2.0%, 1.3%, 0.9%, 0.2% and 1.1%, respectively. 
 DISCUSSION: In Japan, in most cases, consultations by medical staffs are not covered 
by health insurance but free of charge. Meanwhile, based on “the Services and Sup-
ports for Persons with Disabilities Act”, community services are provided at a cost of 
municipalities. Under such a circumstance, many of Japanese patients with mental 
disorders utilize psychosocial supports provided by local governments as well as those 
covered by health insurance. CONCLUSIONS: Costs for psychosocial supports borne 
by local governments is not included in health care cost. However, when conducting 
pharmacoeconomic analysis of psychotropics in Japan, it should be taken into 
account.
